European Psychiatry - Volume 33 - March 2016

278 / 812

S274 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
Aims To ensure that psychiatrists have sufficient knowledge
regarding rTMS. A good knowledge will most likely have a positive
impact on their attitude.
Methods Cross-sectional study was conducted through an online
survey. The study population is all psychiatrists in Saudi Arabia. A
new valid and reliable questionnaire was developed.
Results Sample of 96 psychiatrists enrolled in the study, 81%
were males. Participant’s mean age was 37 years. Half of partic-
ipants were consultants. The sample mainly consists of general
psychiatrists (65%). The study showed that 80% of psychiatrists
have an efficient knowledge about rTMS. Consultants have higher
knowledge than residents do. Abroad training has no association
with the level of knowledge or attitude. Seventy-nine percent of
psychiatrists have a positive attitude toward rTMS. Only 53% of psy-
chiatrists agreed to receive (rTMS) in case they were in a psychotic
depressive condition. Minority (7%) of psychiatrists would not refer
their patients for rTMS.
Conclusion Most of psychiatrists have a good knowledge and a
positive attitude toward rTMS. Those who have high level of train-
ing and experience show higher level of knowledge. Articles are
found to be a better source for updating knowledge. Having an
rTMS treated person in the family or relatives will positively affect
the psychiatrist’s attitude.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW456
Changes in symptom severity and
biochemical markers of brain injury
in patients with treatment-resistant
schizophrenia
N. Petrova ∗, M. Dorofeikova , V. Dorofeykov , M. Ivanov ,
D. Zubov
1 Saint Petersburg State university, medical faculty, Saint-Petersburg,
Russia
2 D.O. Ott research institute of obstetrics - gynecology and
reproductology, laboratory of biochemistry, Saint-Petersburg, Russia
3 Saint-Petersburg V.M. Bekhterev psychoneurological research
institute, department of biological therapy, Saint-Petersburg, Russia
∗ Corresponding author.
One of the major problems of the methodology of translational
research is to find biomarkers that serve as indicators of treatment
response.
The aim was to study the dynamics of biochemical markers in the
process of combined antipsychotics and electroconvulsive therapy.
Material and methods Present study was conducted in 34
patients with treatment-resistant schizophrenia (31.6 ±9.4 years
old) that underwent combined ECT (10 ECTs on average) and
pharmacological treatment. The assessment included PANSS and
determination of NSE and S100B protein concentrations using auto-
mated immunochemical analyzer “Elecsys 2010”. Blood samples
were obtained before the beginning of ECT, 24 hours after the third
and sixth ECTs.
Results Average reduction of PANSS score was 29,1%, > 20% for
85% of patients. There were no significant differences in NSE and
S100B concentrations at different stages of treatment. This result
is consistent with data on the safety of ECT from the point of
view of the integrity of cells. There were found statistically sig-
nificant differences between S100B concentration in women and
men (60 ± 18 and 43 ±23 ng/L, respectively, P = 0.029) and a trend
of increase in S100 levels with the increase of disease duration
(r= 0.372, P= 0.062). Serum S100B concentrations at baseline nega-
tively correlatedwith positive and negative symptoms severity and
with PANSS composite score. No correlation between treatment
efficiency and biochemical markers’ levels was found.
Conclusion Combined antipsychotic and electroconvulsive ther-
apy was effective for treatment-resistant schizophrenic patients
and did not induce nerve cells damage. Initial symptom severity
was correlated with S100B levels.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW457
ECT-treatment in Western Norway;
first data from the Regional register of
neurostimulation treatment
U. Kessler ∗, H. Schoeyen
1 Haukeland university hospital, clinic for psychosomatic medicine,
Bergen, Norway
2 Stavanger university hospital, department of psychiatry,
Stavangerno, Norway
∗ Corresponding author.
Introduction Electroconvulsive therapy (ECT) is one of the most
polarizing treatments inmedicine. Although the treatment effect is
well documented in clinical studies, there is a lack of data regarding
patients treated in an ordinary clinical setting. In 2013, we estab-
lished a regional register of neurostimulation treatment inWestern
Norway.
Objectives To describe the use of ECT at the Haukeland university
hospital in Bergen.
Methods Patients treated with ECT between June 2013 and June
2015 were included in the register.
Results One hundred and forty-seven patients received ECT dur-
ing the 2 years period. The mean age was 58.4 years (22–91 years),
67% were female. Half of the patients (49.7%) had been treated
with ECT previously. Indication for treatment was depression in
137 patients (93.2%), of which 29 (19.7%) were moderately, and
69 patients (46.9%) severely depressed, and additional 37 patients
(25.2%) presented with severe depression with psychotic features.
All but two patients were treated with right unilateral electrode
placement, with a mean of 9.7 (3–22) treatments.
ThemeanMADRS before treatment was 34.2 (4–56) and after treat-
ment 11.9 (0–39). One hundred and ten patients (74.8%) responded
to treatment; of which 89 (60.5%) remitted (response defined as
a 50% or greater decrease from MADRS baseline score, remission
defined as MADRS ≤ 12). Twenty patients (13%) continued with
continuation or maintenance ECT after the index series.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW458
Repetitive transcranial magnetic
stimulation (rTMS) for the
management of treatment-resistant
depression in schizophrenia
S. Mosolov ∗, N. Maslenikov , E. Tsukarzi
Moscow research institute of psychiatry, therapy of mental disorders,
Moscow, Russia
∗ Corresponding author.
Introduction Depression is the most common co-occurring syn-
drome in schizophrenia, which affects up to 60% of patients.
Depression aggravates negative symptoms and cognitive deficit
and can deteriorate social functioning, quality of life and outcome
of the disease. Insufficient clinical response to adequate pharmaco-
therapy determines rising interest to brain stimulation techniques
such as rTMS.